Publication

Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.

Conteduca, V
; 
Crabb, S
; 
Scarpi, E
; 
Hanna, C
; 
Maines, F
; 
Joyce, Helen
; 
Fabbri, P
; 
Derosa, L
; 
Massari, F
; 
Lolli, C
... show 5 more
Citations
Altmetric:
Abstract
Prostate-specific antigen (PSA) decline by 50 % from the baseline to 12 weeks (PSA50w12) is currently used to predict response to treatment and clinical outcome of patients with metastatic castration-resistant prostate cancer (mCRPC). We evaluated the association between PSA changes at 4 weeks and clinical outcome.
Authors
Conteduca, V
Crabb, S
Scarpi, E
Hanna, C
Maines, F
Joyce, Helen
Fabbri, P
Derosa, L
Massari, F
Lolli, C
Zarif,S
Jones, R
Caffo, O
Elliott, Tony
De Giorgi, U
Affiliation
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS, Via Piero Maroncelli 40, 47014, Meldola, FC, Italy
Description
Date
2016-03-28
Publisher
Collections
All Christie Publications
Load more
Show all metadata
Keywords
Type
Article
Citation
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. 2016: Mol Diagn Ther
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/605664
Embedded videos